Denifanstat for moderate‐to‐severe acne: A Phase 2, randomized, double‐blind, placebo‐controlled trial

Denifanstat 50 mg once daily for 12 weeks was generally well tolerated and showed potential to reduce total lesion counts in moderate-to-severe acne vulgaris. Larger and longer term studies are needed to confirm efficacy and safety.

Authors

Institutions

Publication Details

Journal
Journal of the European Academy of Dermatology and Venereology
Published
2025-11-04
DOI
https://doi.org/10.1111/jdv.70119
Primary Topic
Acne and Rosacea Treatments and Effects
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Denifanstat for moderate‐to‐severe acne: A Phase 2, randomized, double‐blind, placebo‐controlled trial

Aie Xu, Jinzi J. Wu, Lunfei Liu, Rixin Chen et al.
Journal of the European Academy of Dermatology and Venereology
Acne and Rosacea Treatments and Effects
article

Denifanstat for moderate‐to‐severe acne: A Phase 2, randomized, double‐blind, placebo‐controlled trial

Aie Xu, Jinzi J. Wu, Lunfei Liu, Rixin Chen, Rong Xiao, Leihong Xiang, Liming Wu, Chunlei Zhang, Jinyan Wang, Yan Lü, He Li, Yanyan Feng, Xunyi Dai, Qin‐yi Chen, Yuemei Yan, Ying Gao
article en

Abstract

Denifanstat 50 mg once daily for 12 weeks was generally well tolerated and showed potential to reduce total lesion counts in moderate-to-severe acne vulgaris. Larger and longer term studies are needed to confirm efficacy and safety.

Journal of the European Academy of Dermatology and Venereology
Central South University (CN), Peking University (CN), Fudan University (CN), Kunming Medical University (CN), The Fourth People's Hospital (CN), Ningbo No. 2 Hospital (CN), Nanyang Institute of Technology (CN), First Affiliated Hospital of Kunming Medical University (CN), Third People's Hospital of Hangzhou (CN), Wuxi No.2 People's Hospital (CN), Chengdu Second People's Hospital (CN), Nanyang Medical College (CN), Second Affiliated Hospital of Nanjing Medical University (CN), Peking University Third Hospital (CN), Hangzhou DAC Biotech (China) (CN), The First People's Hospital of Guiyang (CN), Central Hospital of Wuhan (CN), Affiliated Hangzhou First People's Hospital, Westlake University, School of Medicine (CN), Second Xiangya Hospital of Central South University (CN), Huashan Hospital (CN), Ningbo No.6 Hospital (CN), First Affiliated Hospital Zhejiang University (CN), Zhejiang University (CN), Nanjing Medical University (CN)
Openalex Percentile: Top 47%
Acne and Rosacea Treatments and Effects
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.